# A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Study · id `cardio:ct-nct01713530` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01713530](<https://clinicaltrials.gov/study/NCT01713530>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01713530

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 274 participants.

## Technical summary

Registry record NCT01713530. Randomized; no masking; primary purpose treatment. Start 2013-02-21 (actual); primary completion 2014-01-09 (actual). Results posted on 2015-11-17.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 274 participants (enrolled count; ClinicalTrials.gov record NCT01713530, source copy `cardio:ctgov-nct01713530-2018-04-02`, retrieved 2026-10-26)
- Started: 2013-02-21 (actual) (ClinicalTrials.gov record NCT01713530, source copy `cardio:ctgov-nct01713530-2018-04-02`, retrieved 2026-10-26)
- Primary completion: 2014-01-09 (actual) (ClinicalTrials.gov record NCT01713530, source copy `cardio:ctgov-nct01713530-2018-04-02`, retrieved 2026-10-26)
- Completion: 2014-01-09 (actual) (ClinicalTrials.gov record NCT01713530, source copy `cardio:ctgov-nct01713530-2018-04-02`, retrieved 2026-10-26)
- Results first posted: 2015-11-17 (ClinicalTrials.gov record NCT01713530, source copy `cardio:ctgov-nct01713530-2018-04-02`, retrieved 2026-10-26)
- Countries: United States; Algeria; Austria; France; Norway (ClinicalTrials.gov record NCT01713530, source copy `cardio:ctgov-nct01713530-2018-04-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01713530-2018-04-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): insulin degludec/insulin aspart
- Intervention (Drug): insulin degludec
- Intervention (Drug): insulin aspart
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial (`cardio:pubmed-26592732`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 60640c0fb48880d99e14c9166f9ca426f0db3b124386e4e160f9a21d370f5e63
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
